Exela Pharma Sciences, LLC, (Exela) is expanding their recall, adding fourteen (14) lots to the ongoing voluntary recall of forty-nine (49) lots of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial, 20-count carton.
The FDA is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia (denosumab).
Dialysis Providers: The Centers for Medicare & Medicaid Services (CMS) End Stage Renal Disease Quality Incentive Program (ESRD QIP) reminds you that the payment year (PY) 2023 ESRD QIP preview period o
The Centers for Medicare & Medicaid Services (CMS) issued a final rule that updates Medicare enrollment and eligibility rules to expand coverage for people with Medicare and advance health equity.
This announcement is to notify dialysis facilities that the Centers for Medicare & Medicaid Services (CMS) has extended the End Stage Renal Disease (ESRD) Quality Reporting System (EQRS) clinical data submission deadline for August 2022 data b
Published: October 13, 2022
Exela Pharma Sciences, LLC, (Exela) is voluntarily recalling 49 lots of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial, 20- count carton, to the consumer level.
FDA MedWatch: July 29, 2022
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.
The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and the public on the potential for recurrence of COVID-19 or “COVID-19 rebo